News

AddToAny

Google+ Facebook Twitter Twitter

Vaccine to treat lung cancer

A first-of-its-kind treatment vaccine has moved into a phase I clinical trial for patients with non-small cell lung cancer.

AST-VAC2 is a collaboration agreement between Cancer Research UK and Asterias Biotherapeutics Inc.

Cancer Research UK will manage the initial clinical development of AST-VAC2, which is a promising immunotherapy candidate that is derived from a standardised human embryonic stem cell line.

If shown to be safe and effective, it’s hoped that AST-VAC2 could be used as an additional treatment for patients who no longer have advanced disease, but whose lung cancer is at high risk of coming back, or in combination with other treatments for patients with advanced disease.

Dr Nigel Blackburn, Cancer Research UK’s Director of drug Development, said: “This vaccine trial is a pioneering approach to improving treatment for lung cancer, the biggest cause of cancer death worldwide.

“By coupling our expertise with a leading biotechnology company, we’ve accelerated the development of this experimental treatment by years.”

Related Articles

Autoimmunity symposium

Autoimmunity symposium

To celebrate the launch of the Zenit PRO, Menarini Diagnostics hosted an Autoimmunity symposium. This was attended by scientific staff from across the country despite very challenging weather conditions. The following is an account by Ms Amani Elhouderi of Imperial College Healthcare NHS Trust; reflecting on the day’s events.

Modified flu virus that targets and kills cancer cells

Scientists from Queen Mary University of London have received a grant from Prostate Cancer UK, as London continues to lead the way in advanced prostate cancer research.

Under the microscope: Streptomyces sp. myrophorea

This month: Streptomyces sp. myrophorea

Journal-based learning exercises

Each article’s contents should be read, researched and understood, and you should then come to a decision on each question. The pass mark is 17 out of 20 questions answered correctly. JBL exercises may be completed at any time until the published deadline date. Please select your choice of correct answers and complete the exercises online at: www.ibms.org/cpd/jbl

Top